文献速递临床试验与 GCP基础与转化研究

间充质干/基质细胞治疗头颈癌放疗后唾液分泌减少与口干症的有效性和安全性(MESRIX-III):单中心、双盲、随机、安慰剂对照II期研究方案

Effectiveness and safety of mesenchymal stem/stromal cell for radiation-induced hyposalivation and xerostomia in previous head and neck cancer patients (MESRIX-III): a study protocol for a single-centre, double-blinded, randomised, placebo-controlled, phase II study.
PubMed 文献 · Trials · 2023-09-01

该研究为单中心、双盲、随机、安慰剂对照、平行组、前瞻性II期试验,计划纳入120例丹麦既往接受头颈癌放疗的患者,按1:1随机接受超声引导下同种异体脂肪来源间充质干细胞(ASC)或安慰剂注射至下颌下腺,主要终点为无刺激全唾液流率变化,评价安全性与有效性。

要点

  • 同种异体ASC注射下颌下腺治疗放疗后口干症,主要终点为无刺激全唾液流率变化
  • 计划纳入120例既往头颈癌放疗患者,ASC组与安慰剂组各60例,1:1随机分组
  • 次要终点包括刺激全唾液流率、生活质量、唾液成分、安全性和HLA免疫反应

核心结论

  • 该试验将评估ASC注射下颌下腺作为放疗后口干症潜在新疗法的有效性和安全性,作者希望结果能为改善口干症患者提供临床相关治疗。

研究设计与样本

  • 单中心、双盲、随机、安慰剂对照、平行组、前瞻性II期试验,计划纳入120例丹麦既往接受头颈癌放疗的患者,按1:1区组随机分为ASC组(n=60)和安慰剂组(n=60),超声引导下注射至下颌下腺。
  • 安慰剂为CryoStor10(BiolifeSolutions),即含10%二甲基亚砜(DMSO)的ASC冻存液。
  • 患者在基线(治疗前)、4个月后和12个月后接受评估;除解冻和准备注射治疗的研究人员外,所有研究人员和参与者均对分组设盲,非盲研究人员不参与结局评估。

主要发现

  • 主要终点为无刺激全唾液流率的变化。
  • 次要终点包括刺激全唾液流率变化、生活质量、唾液成分,以及安全性和对干细胞的免疫反应(人类白细胞抗原(HLA)反应)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A predominant side effect of radiotherapy for head and neck cancer is salivary gland hypofunction and xerostomia leading to debilitating oral disorders and impaired quality of life (QoL). Intraglandular mesenchymal stem cell therapy has shown promising results as a treatment for xerostomia. METHODS: This is a randomised, double-blinded, placebo-controlled, parallel-group, prospective, single-centre trial investigating the safety, tolerability, and effectiveness of allogeneic stem cells as a treatment for radiation-induced hyposalivation and xerostomia for previous head and neck cancer patients. We will include a total of 120 patients who previously have been treated with radiotherapy for a head and neck cancer in Denmark. Participants will be randomly assigned using block randomisation to one of two parallel groups in a 1:1 ratio to receive ultrasound-guided injection of allogeneic adipose-derived mesenchymal stem cell (ASC) (n = 60) or placebo (n = 60) into the submandibular glands. Placebo will consist of CryoStor10 (BiolifeSolutions), the freeze media for ASCs containing 10% dimethyl sulfoxide (DMSO). The primary endpoint is change in unstimulated whole saliva flow rate. The secondary endpoints are change in stimulated whole saliva flow rate, QoL, and composition of saliva. Further secondary endpoints are safety and immune response (human leukocyte antigen (HLA) response) to the stem cells will be assessed. Patients are evaluated at baseline (before treatment), after 4 months, and after 12 months. All study personnel, except study personnel thawing and preparing the treatment for injection, and participants will be blinded to group assignment. Unblinded study personnel will not participate in the outcome assessment. DISCUSSION: The trials will investigate the efficacy and safety of ASC injection to the submandibular gland as a potential new treatment for post-radiation xerostomia. We hope the results will pave the way for a clinically relevant treatment to ameliorate patients with xerostomia, a severely hampering condition. TRIAL REGISTRATION: The study is approved by the Danish Data Protection Agency (protocol number P-2020-1164), the National Ethics Committee protocol number: (Protocol number: 1802872), and the Danish Medical Agency (2018-000348-24). The protocol was registered at the ClinicalTrials.gov database (NCT04776538).

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Jakobsen KK, Carlander AF, Grønhøj C, et al. Effectiveness and safety of mesenchymal stem/stromal cell for radiation-induced hyposalivation and xerostomia in previous head and neck cancer patients (MESRIX-III): a study protocol for a single-centre, double-blinded, randomised, placebo-controlled, phase II study. Trials. 2023. PMID: 37658468. doi:10.1186/s13063-023-07594-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。